BioWorld

Feb. 8, 2010

Carping Over PARPs: Buyout Equals 'Negative' for BioMarin?

With promising early data and a clear Phase III pathway for its GALNS drug in a rare lysosomal storage disorder, BioMarin Pharmaceuticals Inc. said it is no longer in critical need of late-stage assets to fill out its pipeline. (BioWorld Today) Read More

Optimer Reports More Good Data for Phase III Fidaxomicin

Gene Panel Recommendations Called a Patent 'Slippery Slope'

Myriad Ruling Could Have Broad Biotech Implications

We've Come a Long Way, Baby, and We're Going a Lot Further

Privately Held Specialty Pharma EUSA Gets $25M Credit Facility

Clinic Roundup

Other News To Note

Bench Press

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Wuxi Apptec insists it’s ‘not a Chinese military company’

BioWorld

Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...

Researchers hit back after colleagues removed from ADA meeting

BioWorld

Former principal officers of the American Diabetes Association (ADA) have hit back at the association’s board and CEO after it prohibited the distribution of an...